Enabling personalized medicine through an interoperable IT infrastructure: An overview of the cancer Biomedical Informatics Grid®

Personalized Medicine

Volumn 6, Issue 4, 2009, Pages 439-448

  Buetow, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

caBIG ; Cancer Biomedical Informatics Grid; Collaboration; Data sharing; Interoperability; IT infrastructure; Personalized medicine; Translational research

Indexed keywords

PANITUMUMAB; TRASTUZUMAB;

CANCER GENETICS; CANCER MODEL; CANCER RESEARCH; CHILDHOOD CANCER; CLINICAL MEDICINE; COMMUNITY; COMPUTER PROGRAM; DRUG COST; ELECTRONIC MEDICAL RECORD; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INFORMATION TECHNOLOGY; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STANDARD;

EID: 67949123281     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.18     Document Type: Review

References (13)

1. Dowsett M, Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 14(24), 8019-8026 (2008).
2. Davies JM, Goldberg RM: First-line therapeutic strategies in metastatic colorectal cancer. Oncology 22(13), 1470-1479 (2008).
3. Frueh FW, Amur S, Mummameni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United State Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
4. The Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
5. Mullighan G, Su X, Zhang J et al.: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360(5), 470-480 (2009).
6. Oster S, Langella S, Hastings S et al.: caGrid 1.0: an enterprise grid infrastructure for biomedical research. J. Am. Med. Inform. Assoc. 15(2), 138-149 (2008).
7. Dave SS, Fu K, Wright GW et al.: Molecular diagnosis of Burkitt's Lymphoma. N. Engl. J. Med. 354, 2431-2442 (2006).
8. DesRoches CM, Campbell EG, Rao SR et al.: Electronic health records in ambulatory care - a national survey of physicians. N. Engl. J. Med. 359(1), 50-60 (2008).
9. Madhaven S, Zenklusen JC, Kotliarov Y et al.: REMBRANDT: helping personalized medicine become a reality through integrative translational research. Mol. Cancer Res. 7(2), 157-167 (2009).
10. Langella S, Oster S, Hastings S et al.: The Cancer Biomedical Informatics Grid (caBIG) Security Infrastructure. AMIA Annu. Symp. Proc. 11, 433-437 (2007)
11. Steele F: Personalized medicine: something old, something new. Pers. Med. 6(1), 1-5 (2009).
12. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
13. Need AC, Motulsky AG, Goldstein DB: Priorities and standards in pharmacogenetic research. Nat. Genet. 37(37), 671-681 (2005).